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ABSTRACT 
Objectives:  A case-control study was conducted to find the prevalence of abnormal blood indices and 
electrolytes in patients with dementia. 
Material & Methods:  The levels of erythrocytes, leukocytes, platelets, electrolytes, and ESR were determined 
from the biochemistry lab. A t-test was applied to see the significance of the difference between each dementia 
patient group (Alzheimer Disease-AD, Parkinson’s Disease-PD, and Frontotemporal Dementia-FTD) with the 
control group for each CBC and electrolyte parameter. 
Results:  In each patients’ groups (AD, PD, and FTD), the mean value of every erythrocyte was lower than the 
normal range. A significant difference existed for each erythrocyte between dementia patients and controls, 
except MCHC. Low levels were observed in neutrophils in all groups of dementia including control group. Very 
high levels were observed in ESR in all groups of dementia. Significant differences existed in the WBC levels 
between controls and AD as well as PD patients, in platelets between the control group and FTD patients, and in 
ESR in each group of dementia patients vs. control group. Normal values observed in all groups of dementia 
patients as well as in the control group. Significant differences existed for sodium and potassium levels between 
the control group and frontotemporal dementia cases. 
Conclusion:  We found low levels in erythrocytes in cases of Alzheimer disease, Parkinson’s disease, and 
frontotemporal dementia. Age-related changes to hematological indices especially related to RBCs, and 
inflammatory mediators like cytokines, hamper the microcirculation in the cerebral tissue leading to micro-
infarcts or microbleeds which cause neuronal insults and parenchymal damage. 
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INTRODUCTION 
The current study was performed on dementia 
patients from the South Punjab Population of 
Pakistan to assess and compare the levels of 
erythrocytes, leukocytes, and electrolytes with the 
healthy control group. Dementia is a neurological 
disorder common in the elderly population. 
People suffer from cognitive and behavioral 
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changes and a varying degree of memory 
impairment. Up to 18% of the population (around 
50 million people) of the world goes into 
neuropsychiatric disorders. They deteriorate in 
their thinking, memory, emotional and social 
behavior. 70% of the dementia of the world is 
attributed to Alzheimer's disease. This disease 
taxes heavily on the economy and psychology of 
the caretakers and families of the patients.1-3 
Common neurodegenerative diseases are 
Alzheimer’s disease (AD), Huntington’s disease, 
Frontotemporal dementia (FTD), and Parkinson’s 
disease (PD). 
 The many causes of dementia include 
hypothyroidism, vitamin deficiencies, chronic 
alcohol abuse, brain tumors, subdural 
hematomas, psychiatric, depression, traumatic 
brain injury, infections (HIV), and chemotherapy-
related cognitive dysfunction.1-4 
 Dementia prevails in the elderly and goes 
proportionally with advancing age. Over 94 years 
of age, nearly 58% of people get dementia. 
Dementia is not always irreversible. Newer 
interventions are helpful. The highest degree of 
clinical expertise is crucial to manage and 
properly recognize the neuropsychiatric 
symptoms of dementia.4 People with dementia 
develop symptoms due to neurochemical, 
neuropathological, and genetic factors. They 
develop Apraxia, which is an inability to perform 
previously learned tasks. The impaired executive 
function of judgment, reasoning, planning, and 
Agnosia. The cerebral cortex suffers from 
inflammation, following injury. Synaptic function 
and metabolism of neurons decline to lead to 
cognitive impairment.5-6 Dementia’s early phase 
slowly progresses and goes overlooked. The 
patient is forgetful, generally confused in time 
and space. In the middle phase, the symptoms are 
more defined and obvious to the caregivers. 
Patients experience uneasy swallowing of food, 
dysequilibrium, speech problems, confusion, or 
memory. They also report an inclusive of unease 
in swallowing and eating, having balance 
problems, language and speech difficulties, 
memory impairment, forgets names or events, 
changes in behavior, restlessness, wandering 
around and repeatedly questioning), 
forgetfulness of people’s names and recent 
events. They often require more help with 
problem-solving, communication, and attention.  
During the last phase, memory disturbance is 
marked. Cannot identify nearby relatives, places, 
or events. There is aggressiveness, crying, or 
anger.7-8 
 In clinical practice, behavioral and psychiatric 
disorders exhibit a variety of cognitive and non-
cognitive symptoms. Patients ultimately develop 
behavioral or psychiatric symptoms in over 90% 
of the cases of dementia. The behavioral and 
psychological symptoms of dementia (BPSD) 
includes hallucinations, anxiety, depression, 
agitation, disinhibition, elation, apathy, irritability, 
delusions, aberrant motor behavior, and appetite 
or sleep changes. The BPSD tends to have a poor 
outcome in psychiatric patients as hospital stay 
and health care costs come into play in the long-
term sequelae of the disease. It involves the 
misuse of drugs, agitation, or distress of the 
caregivers and the patients as well.9-11 Symptoms 
in patients either exist simultaneously or occur 
individually. In clinical practice, it is better to 
group the symptoms of BPSD patients for 
estimation of prognosis, the response of 
treatment, and the natural course of disease 10-11. 
The dementias have some risk factors. Age is the 
biggest risk factor. Symptoms increase as the age 
advances. First-degree relatives of Alzheimer's 
patients have a higher risk. The genetic 
component apoE4 (Apolipoprotein E) has a role 
to play. Other risk factor includes lifestyle, 
diabetes, and hypertension, the intensity of 
mental engagement through life, play significant 
role.9 
 Cortical and sub-cortical types of dementia is 
a classification used by Psycho-neurolinguistics. 
Cortical dementia (CD) includes Alzheimer 
Disease (AD), Frontotemporal Dementia (FTD), 
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Creutzfeldt-Jakob disease (CJD) while Subcortical 
dementia (SCD) includes Progressive supranuclear 
palsy, Parkinson’s Disease (PD) and Huntington's 
Disease (HD).9,12 Parkinson’s disease is a 
progressive neurodegenerative disorder that 
occurs when substantia nigra cells start dying. 
There is no test that persistently differentiates PD 
from other neuropsychiatric disorders. History 
and examination remain the mainstay for 
diagnosis. The patient has slowness and difficulty 
of movements and rigidity of limbs. PD can also 
be caused due to infarctions of the cerebrum, or 
its degeneration like, multiple system atrophy or 
progressive supranuclear palsy.13 Frontotemporal 
dementia (FTD) is another progressive 
neurodegenerative disorder when atrophy of 
frontal and temporal lobes occurs. Here the 
patient has all the common neurodegenerative 
symptoms along with personality change, bizarre 
effect, and aphasia.14 Alzheimer’s disease includes 
the affected area affected in Alzheimer's is the 
medial temporal and temporoparietal cortex. It 
starts with memory loss. There is amyloid protein 
deposition outside neurons and neurofibrillary 
tangles inside the cells that contribute to senile 
plaque formation. Amyloid plaques are formed by 
extracellular deposition of Aβ.15 
 
MATERIALS AND METHODS 
Study Design, Setting & Population 
A case-control study was conducted during 2018-
2019, at Bahauddin Zakariya University (BZU), 
Multan, Pakistan, to find the prevalence of 
abnormal blood indices and electrolytes in 
patients with dementia disease. 
 
Inclusion Criteria 
The dementia patients (N = 35) and the healthy 
individuals as the control group (N = 15) were 
enrolled from South Punjab. Following groups of 
dementia patients were included: Alzheimer 
Disease (AD), Parkinson’s Disease (PD) and 
Frontotemporal Dementia (FTD). Patients 
belonged to Kot Addu, Taunsa, Multan, Shujabad, 
Dera Gazi Khan, and Bahawalpur stations. 
 
Diagnosis of Dementia 
The diagnosis of dementia was done via. either 
MRI or CT scans. In some of the patients, the PET 




Patients suffering from malignancies not will to 
become part of the study. 
 
Blood Sampling 
Blood samples of dementia patients were 
collected from Fatima Medical Center, Multan. 
The blood samples of healthy controls were also 
collected from Fatima Medical Center, Multan. 
 
Laboratory Testing 
The blood samples were sent to the biochemistry 
laboratory of Fatima Medical Center. The levels of 
erythrocytes, leukocytes, platelets and ESR were 
determined through the complete blood count 
(CBC) test in both patients’ groups as well as in 
control group. Serum electrolytes (Sodium & 
Potassium) were also determined from 
biochemistry laboratory tests. 
 
Data Collection & Analyses 
The data was collected for the information on 
age, gender, location, medication intake, 
existence of diabetes mellitus (DM). The 
descriptive statistics including frequencies, mean 
values, minimum/maximum values were analyzed 
via. SPSS version 25. Each parameter of CBC and 
electrolytes were compared with the normal 
ranges. 
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Statistical Analyses 
A t-test was applied to see the significance of 
difference between each dementia patient group 
(AD, PD & FTD) with the control group for each 
CBC and electrolyte parameter. A p-value less 
than 0.050 was considered the significant. 
 
RESULTS 
Age of the Patients 
The mean age of the dementia patients was 70 
years, whereas, the mean age of the control 
group was 65 years. 
 
Gender Distribution 
There were more female patients (62.85%) as 
compared to male patients (37%). Majority of the 
patients were from rural areas (51.4%). 
 
Clinical Information 
Table 1 shows the complete detail of information 
for both groups. The control group was not 
taking any medication. Dementia patients were 
on medication. Both group individuals were not 
diabetic. The included dementia patients people 
were not having any other diseases. However, 
they were found the intake of the following drugs 
for dementia: Donepezil, Memantine, Quetiapine, 
 
Table 1: Sociodemographic Information of Dementia 







Mean: 70;  
Minimum:60;  
Maximum:80 
Mean: 65;  
Minimum: 50;  
Maximum: 80 
Gender 
Male: 13 (37%);  
Female: 22 (62.85%) 
Male: 7 (46%);  
Female: 8 (53.3%) 
Location  
Rural: 18 (51.4%) 
Urban: 17 (48.5%) 
Rural: 6 (40%) 
Urban: 9 (60%) 
 
Risperidone, Donecept, Valium, Methylcobalamin, 
Alzilo, Sinemet and PK-Merz. 
 
Comparison of Erythrocytes 
Table 2 shows the mean values of each 
erythrocyte in each group of dementia patients 
including a control group. The control group was 
having normal values of almost all parameters 
except, hematocrit and MCHC. However, in 
dementia patients’ groups (Alzheimer Disease, 
Parkinson’s Disease and Frontotemporal 
Dementia) mean value of every erythrocyte 
parameter was lower than the normal range. A 
significant difference existed (p value<0.050) for 
each erythrocyte parameter between each 
dementia patient group (AD, PD, and FTD) and 
control group (Table 3), except MCHC (between 
controls and AD group). 
 











Dementia  (FTD) 
Patients N=11 
Hemoglobin (g/dL) 
Normal Range: 13.5 – 17.5  
13.7 ± 1.64 7.19 ± 0.928 8.90 ± 1.308 10.42 ± 0.681 
Hematocrit (%) 
Normal Range: 42-52 (male), 37 – 47 (female) 
40.6 ± 4.376 27.03 ± 4.027 23.38 ± 1.481 26.4 ± 2.79 
Red Blood Cells (×106/µL)  
Normal Range: 4.5 – 5.9 (male), 4.1 – 5.1 
(female) 
4.87 ± 0.533 2.76 ± 0.608 2.97 ± 0.531 3.06 ± 0.485 
Mean Cell Volume (fL) 
Normal Range: 80 – 94 
87.4 ± 4.656 71.95 ± 4.094 77.48 ± 1.187 70.09 ± 2.213 
Mean Corpuscular Hemoglobin (pg) 29.3 ± 1.790 25.09 ± 1.195 25.63 ± 2.029 25.2 ± 2.188 
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Normal Range: 27.5 – 33.2 
Mean Corpuscular Hemoglobin Concentration 
(g/dL) Normal Range: 33.4 – 35.5  
32.89 ± 0.981 32.89 ± 1.249 31.51 ± 1.180 31.70 ± 1.494 
 
Table 3: Comparison of Erythrocytes via. t-Test. 
Erythrocytes 
Control Group vs. 
Alzheimer Disease 
(AD) Patients 
Control Group vs. 
Parkinson’s Disease 
(PD) Patients 
Control Group vs. 
Frontotemporal Dementia 
(FTD) Patients 
p- value t- test; df p- value t- test p- value t- test 
Hemoglobin (g/dL) < 0.0001 12.24;25 < 0.0001 8.24; 25 < 0.0001 6.22;24 
Hematocrit (%) < 0.0001 11.90;25 < 0.0001 28.28;25 < 0.0001 16.30;24 
Red Blood Cells (millon cells/cmm) < 0.0001 9.60;25 < 0.0001 9.21;25 < 0.0001 8.87; 24 
Mean Cell Volume (fL) < 0.0001 9.03;25 < 0.0001 7.71;25 < 0.0001 11.37;24 
Mean Corpuscular Hemoglobin (pg) < 0.0001 6.98;25 < 0.0001 4.99;25 < 0.0001 5.25;24 
Mean Corpuscular Hemoglobin 
Concentration (g/dL) 




Comparison of Leukocytes 
Table 4 shows the mean values of each leukocyte and 
ESR in each group of dementia patients including a 
control group. Normal ranges were observed between 
white blood cells, eosinophils, and platelets in all 
groups of dementia patients including the control 
group. Low levels were observed in Neutrophils in all 
groups of dementia patients including the control 
group. Very high levels were observed in ESR in all 
groups of dementia patients. According to t-test, 
significant differences (p-value < 0.0001) were existed 
in the WBC levels between the control group and AD 
as well as PD patients. A significant difference (p-value 
< 0.0001) existed in platelets between the
control group and FTD patients. However, significant 
differences (p-value < 0.0001) existed for ESR in each 
group of dementia patients vs control group (Table 5). 
 
Comparison of Electrolytes 
Table 6 shows the mean values of sodium and 
potassium in each group of dementia patients 
including the control group. Normal values observed 
in all groups of dementia patients as well as in the 
control group. Significant differences existed for 
sodium and potassium levels between the control 
group and frontotemporal dementia cases (p values: 
0.0011 & 0.0009) (Table 7). 
 




Alzheimer Disease (AD) 
Patients N=12 
Parkinson’s Disease 




White Blood Cells 
(×103/mm3) 
Normal Range: 4 – 
11×103/mm3 
7546.66 ± 1044.62 9442.85 ± 901.03 8654.54 ± 1860.84 8320.0 ± 1599.16 
Neutrophils (%) 
Normal Range: 49 – 74 
3.60 ± 1.40 4.14 ± 1.40 4.00 ± 1.00 3.50 ± 1.17 
Eosinophils (%) 
Normal Range: 0 – 6 
2.93 ± 1.03 3.28 ± 1.20 2.90 ± 1.22 2.50 ± 1.08 
Platelets (×106/L) 193620 ± 40582.37 199178.57 ± 48574.92 224818.18 ± 46363.38 25100 ± 61029.04 
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Normal Range: 150 – 450 
ESR Normal Range: 0 – 10 
(mm/1st hour) 
12.06 ± 4.13 117.35 ± 7.94 106.72 ± 10.14 80.70 ± 10.77 
 
Table 5: Comparison of Leukocytes, Platelets & ESR via. t-Test. 
Leukocytes 
Control Group vs. Alzheimer 
Disease (AD) Patients 
Control Group vs. 
Parkinson’s Disease (PD) 
Patients 
Control Group vs. 
Frontotemporal Dementia 
(FTD) Patients 
p- value t- test; df p- value t- test p- value t- test 
White Blood Cells (/mm) < 0.0001* 4.97;25 < 0.0001* 1.95;25 0.148 1.49;24 
Neutrophils (%) 0.3288 0.99;25 0.412 0.83;25 0.849 0.19;24 
Eosinophils (%) 0.422 0.81;25 0.9453 0.069;25 0.313 1.03;24 
Platelets 0.745 0.32;25 0.0741 1.86;25 < 0.0001* 8.46;24 









(AD) Patients N=12 
Parkinson’s Disease 
(PD) Patients N=12 
Frontotemporal Dementia 
(FTD) Patients N=11 
Sodium (mmol/L) 
Normal Range: 136-145 
138.8 ± 0.5 138.5 ± 0.6 139 ± 0.7 138 ± 0.6 
Potassium (mmol/L) 
Normal Range: 3.6-5.2 
    4.4 ± 0.2     4.3 ± 0.4     4.6 ± 0.5     4.7 ± 0.2 
 
Table 7: Comparison of Sodium & Potassium via. t-Test. 
Electrolytes 
Control Group vs. Alzheimer 
Disease (AD) Patients 
Control Group vs. Parkinson’s 
Disease (PD) Patients 
Control Group vs. Frontotemporal 
Dementia (FTD) Patients 
p- value t- test; df p- value t- test p- value t- test 
Sodium (mmol/L) 0.165 1.41;25 0.35 0.93;25 0.0011 3.70;24 
Potassium 
(mmol/L) 
0.404 0.84;25 0.16 1.41;25 0.0009 3.77;24 
 
DISCUSSION 
The study reported that the mean of each erythrocyte 
(hemoglobin, hematocrit, RBC, mean cell volume-MCV, 
mean cell hemoglobin-MCH and MCHC) was lower 
than the normal range. Whereas, the control group 
was having normal values of almost all parameters 
except, hematocrit and MCHC. Except for MCHC, the 
significant difference existed for each erythrocyte 
parameter between each dementia patient group 
(Alzheimer Disease-AD, Parkinson’s Disease-PD, and 
Frontotemporal Dementia-FTD) and control group. 
Hemoglobin was associated with increased risks of 
microbleeds and consequently dementias in a number 
of studies. Winchester et al also16 reported low 
hemoglobin ranges in Alzheimer's disease. Although, 
poor cognitive function is reported from anemia, 
however, Winchester et al16 did not find any causative 
impact on cognitive performance from low red blood 
cells. Wolters et al17 mentioned the risk of dementia, 
including Alzheimer’s, associated with both low and 
high serum levels of hemoglobin, as there were 
differences in the integrity of white matter and 
perfusion of cerebral tissue. Anemia is associated with 
the risk of developing any type of dementia in 34% 
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and Alzheimer’s dementia in 41% cases.18 In older 
persons, cognition was impaired in patients with 
higher or lower levels of hemoglobin, and the risk of 
developing Alzheimer’s dementia was higher.19 We 
observed the normal ranges in white blood cells, 
eosinophils, and platelets in all groups of dementia 
patients including the control group. Low levels were 
observed in neutrophils in all groups of our dementia 
patients including the control group. Very high levels 
were observed in ESR in all groups of dementia 
patients. ESR tends to go up in advancing age and is 
more marked in females with dementia. Significant 
differences existed in the WBC levels between the 
control group and Alzheimer's cases as well as 
Parkinson’s cases. A significant difference also existed 
in platelets between the control group and 
Frontotemporal dementia cases. We observed normal 
values in all groups of dementia patients as well as in 
the control group. Significant differences existed for 
sodium and potassium levels between the control 
group and frontotemporal dementia patients. 
 Dementia and cognitive impairment are 
secondary to cerebral infarction. Infarcts arise in 
the brain when there are vascular disturbances 
(embolism, spasms, bleeding, or low blood 
indices like hemoglobin or hematocrit). It is 
known that higher hemoglobin levels pose more 
risk of stroke than normal levels. As the age 
advances, there is more incidence of anemia 
ranging from as low as 4.2% to as high as 28%. 
There is little literature to support this though20. 
With advancing age, the incidence of Alzheimer 
and other forms of dementia increases 
exponentially. The role of anemia as a cause of 
dementia is controversial.19 CBC is generally 
advised in patients for identification of reversible 
dementia. Upon post mortem studies of 
demented human brains, the levels of potassium 
measured intracellularly were in contradiction to 
other studies. The raised intracellularK+ were 
indicating exposure of astrocytes to Aβ.20 Cellular 
potassium was lower in other studies.21 When 
compared to other studies our study contradicts 
their results, as we had normal levels of sodium 
and potassium ions in the brain cells of demented 
patients. Our patients of the study were receiving 
treatment for their dementia. It is likely that 
correction of dementia brought the levels of 
these electrolytes back to normal. Dementia is 
found in patients that have either high or low 
hemoglobin. Cerebrovascular accidents cause 
dementia in these people who exhibit lower 
connectivity to brain infarcts. This, however, is still 
unclear, how hemoglobin relates to dementia.19 In 
Parkinson’s disease, iron plays a significant role. It 
was found accumulated in the substantia nigra.21 
Patients of PD were found to have a progressive 
reduction in hemoglobin content which also 
related to the peripheral metabolism of iron and 
indicated the severity of the disease.23 
Inflammatory cytokines have a deleterious effect 
on erythropoietin leading to worsening of anemia 
with the increasing cytokine.24 The hematological 
indices and electrolytes show the level of 
cognitive dysfunction and it can also be used as a 
diagnostic biomarker for dementia progression in 
the patients of the South Punjab Population, but 
there is a limitation in our study that all patients 
were on the treatment for dementia. 
 
CONCLUSION 
We found deranged erythrocytes in cases of 
Alzheimer disease, Parkinson’s disease and in 
frontotemporal dementia. Age related changes to 
hematological indices especially related to red 
blood cells, and inflammatory mediators like 
cytokines, hamper the microcirculation in the 
cerebral tissue leading to micro-infarcts or micro 
bleeds which cause neuronal insults and 
parenchymal damage, resulting in a progressive 
deterioration in cognition, memory, coordination 
and behavior of the individuals. 
 
RECOMMENDATION 
Adherence to the golden rules of health, physical 
activity and maintenance of healthy diet 
throughout life can lead to dementia free life. This 
was the study from single center on limited data. 
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LIMITATIONS OF THE STUDY 
Larger studies are required to establish the 
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